# Investigation of Tolterodine, Pregabalin and a Tolterodine - Pregabalin Combination for the Treatment of Overactive Bladder

> **NCT00746681** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 188 (actual)

## Conditions studied

- Overactive Bladder

## Interventions

- **DRUG:** Tolterodine & Pregabalin
- **DRUG:** Tolterodine
- **DRUG:** Placebo
- **DRUG:** Tolterodine & Pregabalin
- **DRUG:** Pregabalin

## Key facts

- **NCT ID:** NCT00746681
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** —
- **Final completion:** 2006-11
- **Target enrollment:** 188 (ACTUAL)
- **Last updated:** 2009-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00746681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00746681, "Investigation of Tolterodine, Pregabalin and a Tolterodine - Pregabalin Combination for the Treatment of Overactive Bladder". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00746681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*